High-Content Analysis-Based Sensitivity Prediction and Novel Therapeutics Screening for c-Met-Addicted Glioblastoma
(1) Background: Recent advances in precision oncology research rely on indicating specific genetic alterations associated with treatment sensitivity. Developing ex vivo systems to identify cancer patients who will respond to a specific drug remains important. (2) Methods: cells from 12 patients with...
Main Authors: | Jeong-Woo Oh, Yun Jeong Oh, Suji Han, Nam-Gu Her, Do-Hyun Nam |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/3/372 |
Similar Items
-
Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in <i>MET</i>-Addicted Cancer
by: Jooseok Kim, et al.
Published: (2020-06-01) -
Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
by: Masahiro Ohara, et al.
Published: (2021-03-01) -
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
by: Sally C.M. Lau, MD, MPH, et al.
Published: (2023-10-01) -
The role of HGF/c-MET signaling pathway in lymphoma
by: Bao Quoc Lam, et al.
Published: (2016-12-01) -
Targeting <i>MET</i> Amplification: Opportunities and Obstacles in Therapeutic Approaches
by: Yuichi Kumaki, et al.
Published: (2023-09-01)